Previous Close | 1.1600 |
Open | 1.1600 |
Bid | 0.9400 |
Ask | 1.0000 |
Strike | 92.50 |
Expire Date | 2025-01-17 |
Day's Range | 1.1600 - 1.1600 |
Contract Range | N/A |
Volume | |
Open Interest | 936 |
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma
By buying an index fund, investors can approximate the average market return. But if you pick the right individual...